logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Sook Ryun Park

university of ulsan
H指数:38
被引数:7,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

一线替雷利珠单抗联合化疗对比安慰剂联合化疗在不可切除的局部晚期/转移性食管鳞状细胞癌中的应用：一项随机III期试验（RATIONALE-306）3年生存随访的最低数据

Nature Communications
IF15.7
2026-09-030
OAAI
Harry H. Yoon; Ken Kato; Eric Raymond; Richard Hubner; Yongqian Shu; Yueyin Pan; Sook Ryun Park; Takashi Kojima; Chen-Yuan Lin; Lucjan Wyrwicz; David Tougeron; Ryu Ishihara; Kaijun Wang; Yanyan Peng; Jianming Xu
Is chemoradiotherapy equivalent to surgery for cT1bN0M0 esophageal cancer? A multicenter retrospective study (Korean Radiation Oncology Group 21-10)

化放疗与手术治疗cT1bN0M0食管癌是否等效？一项多中心回顾性研究（韩国放射肿瘤学组21-10）

European Journal of Surgical Oncology
IF2.9
2025-10-310
PRE
Ha Un Kim; Hyeong Ryul Kim; Yong-Hee Kim; Sook Ryun Park; Sung-Bae Kim; Ho June Song; Jae-Uk Jeong; Hak Jae Kim; Sung Ho Moon; Dongryul Oh; Min Kyu Kang; Hun Jung Kim; Jin Hee Kim; Young Seob Shin; Jong Hoon Kim
Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum

基于常规临床、实验室和病理参数的转移性或不可切除食管癌患者接受一线抗PD-1联合氟嘧啶和铂类药物治疗的真实世界结局与生物标志物分析

Cancers 2025, Vol. 17, Page 3149
IF4.4
2025-09-280
OAAI
Jiyun Jeong; Seyoung Seo; Sung-Bae Kim; Joon Seon Song; Hye Ryun Kim; Byoung Chul Cho; Minkyu Jung; Chang Gon Kim; Moonki Hong; Min Hee Hong; Sook Ryun Park
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析

ADVANCES IN THERAPY
IF4
2025-03-010
OAAI
Xu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H.
Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery
ANNALS OF SURGICAL ONCOLOGY
IF3.5
2024-07-020
PRE
Kim, Ji Yong; Yun, Jea Kwang; Kim, Yong-Hee; Park, Seung-il; Lee, Jeong Hoon; Jung, Hwoon-Yong; Lee, Gin Hyug; Song, Ho June; Kim, Do Hoon; Choi, Kee Don; Ahn, Ji Yong; Kim, Sung-Bae; Cho, Kyung-Ja; Ryu, Jin-Sook; Kim, Jong Hoon; Kang, Jihoon; Park, Sook Ryun; Kim, Hyeong Ryul
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09
BMC CANCER
IF3.4
2024-05-092
OAAI
Kim, Sun Young; Kim, Jee Hyun; Kim, Tae-Yong; Park, Sook Ryun; Yoon, Shinkyo; Lee, Soohyeon; Lee, Se-Hoon; Kim, Tae Min; Han, Sae-Won; Kim, Hye Ryun; Yun, Hongseok; Lee, Sejoon; Kim, Jihun; Choi, Yoon-La; Choi, Kui Son; Chae, Heejung; Ryu, Hyewon; Lee, Gyeong-Won; Zang, Dae Young; Ahn, Joong Bae
BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Park, Sook Ryun; Chen, Ming-Huang; Dechaphunkul, Arunee; Ding, Ningning; Lin, Xiao; Zhang, Jinghui; Li, Vivian; Li, Qiao; Ba, Yi
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study

nivolumab和紫杉醇二线化学免疫治疗免疫相关生物标志物富集的晚期胃癌: 一项多中心Ib/II期研究

GASTRIC CANCER
IF5.1
2023-10-315
PRE
Lee, Choong-kun; Lee, Jii Bum; Park, Se Jung; Che, Jingmin; Kwon, Woo Sun; Kim, Hyo Song; Jung, Minkyu; Lee, Seulkee; Park, Sook Ryun; Koo, Dong-Hoe; Lee, Hyun Woo; Bae, Woo Kyun; Jeung, Hei-Cheul; Hwang, In Gyu; Kim, Hyunki; Nam, Chung Mo; Chung, Hyun Cheol; Rha, Sun Young
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
NATURE CANCER
IF28.5
2023-06-1215
PRE
Sung, Changhwan; An, Jinhyeon; Lee, Soohyeon; Park, Jaesoon; Lee, Kang Seon; Kim, Il-Hwan; Han, Ji-Youn; Park, Yeon Hee; Kim, Jee Hyun; Kang, Eun Joo; Hong, Min Hee; Kim, Tae-Yong; Lee, Jae Cheol; Lee, Jae Lyun; Yoon, Shinkyo; Choi, Chang-Min; Lee, Dae Ho; Yoo, Changhoon; Kim, Sang-We; Jeong, Jae Ho; Seo, Seyoung; Kim, Sun Young; Kong, Sun-Young; Choi, Jung Kyoon; Park, Sook Ryun
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA

肿瘤基因组和表观基因组的整合建模，以通过游离DNA增强癌症诊断

NATURE COMMUNICATIONS
IF15.7
2023-04-109
OAAI
Bae, Mingyun; Kim, Gyuhee; Lee, Tae-Rim; Ahn, Jin Mo; Park, Hyunwook; Park, Sook Ryun; Song, Ki Byung; Jun, Eunsung; Oh, Dongryul; Lee, Jeong-Won; Park, Young Sik; Song, Ki-Won; Byeon, Jeong-Sik; Kim, Bo Hyun; Sohn, Joo Hyuk; Kim, Min Hwan; Kim, Gun Min; Chie, Eui Kyu; Kang, Hyun-Cheol; Kong, Sun-Young; Woo, Sang Myung; Lee, Jeong Eon; Ryu, Jai Min; Lee, Junnam; Kim, Dasom; Ki, Chang-Seok; Cho, Eun-Hae; Choi, Jung Kyoon
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

卡博替尼在韩国晚期肝细胞癌患者中的真实世界疗效与安全性：一项多中心回顾性分析

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-05-149
OAAI
Bang, Yeong Hak; Lee, Choong-kun; Yoo, Changhoon; Chon, Hong Jae; Hong, Moonki; Kang, Beodeul; Kim, Hyung-Don; Park, Sook Ryun; Choi, Won-Mook; Choi, Jonggi; Lee, Danbi; Shim, Ju Hyun; Kim, Kang Mo; Lim, Young-Suk; Lee, Han Chu; Ryu, Min-Hee; Ryoo, Baek-Yeol
Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC).
CANCER RESEARCH
IF16.6
2021-07-011
PRE
Young, Rha Sun; Lee, Jii Bum; Kim, Hyo Song; Jung, Minkyu; Lee, Choong-kun; Park, Sook Ryun; Koo, Dong-Hoe; Lee, Hyun Woo; Bae, Woo Kyun; Jeung, Hei Cheul; Chung, Hyun Cheol

研究方向

暂未获取到该数据
M
Min‐Hee Ryu
H 指数:60论文数:522被引数:2.0万
Y
Young‐Woo Kim
H 指数:68论文数:820被引数:2.1万
K
Keun Won Ryu
H 指数:58论文数:352被引数:1.0万
B
Baek‐Yeol Ryoo
H 指数:64论文数:499被引数:1.7万
I
Il Ju Choi
H 指数:63论文数:383被引数:1.3万
Y
Yoon‐Koo Kang
H 指数:93论文数:864被引数:6.0万
C
Chan Gyoo Kim
H 指数:42论文数:206被引数:6,025
S
Soo‐Jeong Cho
H 指数:43论文数:407被引数:6,531
J
Jong Yeul Lee
H 指数:31论文数:123被引数:3,816
B
Byung‐Ho Nam
H 指数:55论文数:291被引数:8,496